The comparative effectiveness of the three commonly used anti-TNF infliximab, etanercept and adalimumab didn’t vary significantly as has been shown in various studies including one meta-analysis of 26 published placebo-controlled RCTs of patients with RA in MTX-resistant populations where the investigators weren’t able to show significant variations in efficacy among the 3 TNF inhibitors. The gene discussed is TNF; the disease is rheumatoid arthritis.